National Clinical Guidelines on Diagnosis and Treatment of Ph-Negative Myeloproliferative Neoplasms (Polycythemia Vera, Essential Thrombocythemia, and Primary Myelofibrosis) (Edition 2024)
Authors:
- Anait Levonovna MelikyanAMAnait Levonovna Melikyan
- I. N. SubortsevaISI. N. Subortseva
- A. M. KovriginaAKA. M. Kovrigina
- V. A. ShuvaevVSV. A. Shuvaev
- E. V. MorozovaEME. V. Morozova
- E. G. LomaiaELE. G. Lomaia
- V. V. BaykovVBV. V. Baykov
- O. Yu. VinogradovaOVO. Yu. Vinogradova
- S. V. GritsaevSGS. V. Gritsaev
- T. I. IonovaTIT. I. Ionova
- P. I. KuznetsovaP. I. Kuznetsova
- Л. А. КузьминаЛКЛ. А. Кузьмина
Open Access
- 1 July 2024
- journal article
- Published by Practical Medicine Publishing House in Clinical oncohematology
- Vol. 17 (3) , 291-334
Abstract
The development of National clinical guidelines on diagnosis and treatment of Ph-negative myeloproliferative neoplasms provides the knowledge basis for decision making in diagnosis, therapy, prevention, and rehabilitation in compliance with evidence-based medicine principles in order to ensure appropriate medical care in a particular clinical setting. The clinical guidelines underly the choice of optimal methods of diagnosis, therapy, prevention, and rehabilitation as part of a patient’s medical care, the development of criteria for the assessment of medical care quality, medical care standards, medical care procedures, setting standards on equipment and management of diagnostic and therapeutic procedures, and provision of continuous medical education and advanced training for healthcare professionals. In 2013, a working group was formed to develop and formulate clinical guidelines on the treatment of myeloproliferative neoplasms. These guidelines were first published in 2014, afterwards they were revised and republished. The dynamic development of current hematology presupposes constant updating of knowledge and implementation of new diagnosis and treatment methods in clinical practice. In this context, clinical guidelines present a dynamic document to be continuously amended, expanded, and updated in accordance with scientific findings and new requirements of specialists who are directly involved in treatment activities. The present edition is an upgraded version of clinical guidelines with updated information on classification, diagnosis, prognosis, current methods of therapy, and their efficacy and tolerability assessment. The guidelines are intended for oncologists, hematologists, healthcare executives, and medical students.Keywords
This publication has 118 references indexed in Scilit:
- Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and managementAmerican Journal of Hematology, 2024
- The prognostic contribution of CBL, NRAS, KRAS, RUNX1, and TP53 mutations to mutation‐enhanced international prognostic score systems (MIPSS70/plus/plus v2.0) for primary myelofibrosisAmerican Journal of Hematology, 2023
- Changing incidence of myeloproliferative neoplasms in Australia, 2003‐2014American Journal of Hematology, 2019
- Primary myelofibrosis: 2017 update on diagnosis, risk‐stratification, and managementAmerican Journal of Hematology, 2016
- Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM groupAmerican Journal of Hematology, 2016
- Validation of the revised international prognostic score of thrombosis for essential thrombocythemia (IPSET‐thrombosis) in 585 Mayo clinic patientsAmerican Journal of Hematology, 2016
- How common are myeloproliferative neoplasms? A systematic review and meta‐analysisAmerican Journal of Hematology, 2014
- Successful treatment of severe extremity pain in myelofibrosis with low‐dose single‐fraction radiation therapyAmerican Journal of Hematology, 2010
- A phase II trial of pegylated interferon α‐2b therapy for polycythemia vera and essential thrombocythemiaCancer, 2006
- Analysis of the androgen response of 23 patients with agnogenic myeloid metaplasia: The value of chromosomal studies in predicting response and survivalCancer, 1982